<p>RNS 编号：6387L Polarean Imaging PLC2025 年 12 月 15 日</p>
<p>2025 年 12 月 15 日</p>
<p>Polarean Imaging Plc</p>
<p>（&#34;Polarean&#34;或&#34;公司&#34;）</p>
<p>股东大会结果</p>
<p>关于帮助股东的匹配交易设施的信息</p>
<p>Polarean Imaging plc（AIM：POLX），一家商业阶段的医疗技术公司和功能性肺部成像的全球领导者，使用超极化氙 MRI，宣布在今天早些时候举行的公司股东大会（&#34;股东大会&#34;）上，所有决议均已通过投票通过。</p>
<p>投票结果的详细信息如下：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>决议编号</td>
<td>名称</td>
<td>支持票数</td>
<td>支持票比例</td>
<td>反对票数</td>
<td>反对票比例</td>
<td>投票弃权 *</td>
</tr>
<tr>
<td>1</td>
<td>取消决议</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>重新注册和采纳新章程决议</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
<p>* 注：根据英国法律，&#34;投票弃权&#34;不算作投票，并不计入支持或反对决议的计算中。</p>
<p>有效的代理指示已收到，涉及 664,456,630 股普通股，约占公司已发行股本的 55.05%。</p>
<p>截至 2025 年 12 月 15 日，已发行普通股总数为 1,207,032,781 股。</p>
<p>在股东大会上提出并通过的决议的完整文本可以在公司于 2025 年 11 月 14 日发布的通函中找到，其中包括股东大会通知（&#34;通函&#34;），并可在公司网站上查阅。公告中使用但未定义的专有名词应与通函中赋予的含义相同。</p>
<p>AIM 取消</p>
<p>在股东大会上获得股东批准后，普通股在 AIM 的交易将被取消。取消预计将在 2025 年 12 月 23 日上午 7:00 进行，因此，普通股在 AIM 的最后交易日预计为 2025 年 12 月 22 日。</p>
<p>重新注册为私人公司</p>
<p>根据决议 2 的通过，公司将重新注册为私人有限公司，并采纳新章程，预计将在 2026 年 1 月 12 日之前完成。</p>
<p>匹配交易设施</p>
<p>公司已安排匹配交易设施，以帮助股东在取消之日起交易普通股。匹配交易设施将由 J P Jenkins 提供，J P Jenkins 是 Prosper Capital LLP 的指定代表，后者已获得英国金融行为监管局的授权和监管。在匹配交易设施下，股东或希望购买或出售普通股的人可以通过其股票经纪人向 J P Jenkins 留下他们愿意购买或出售的普通股数量及其愿意的价格。如果 J P Jenkins 能够将该订单与相反的卖出或买入指令匹配，它将联系双方并进行交易。取消生效后，匹配交易设施将开始，详细信息将提供给股东，并可在公司网站（www.polarean.com）上查阅。然而，需要注意的是，无法保证该设施在取消后能为普通股提供流动性。</p>
<p>股东将继续能够以无证书形式（即在 CREST 中）持有其股份，并应与其现有的股票经纪人核实他们是否愿意或能够交易未上市股份。</p>
<p>匹配交易设施预计将在取消后至少运行十二个月。目前的意图是它将继续超过该时间段，但股东应注意，它可能会在短时间内撤回，从而限制股东交易普通股的能力。董事会将持续审查匹配交易设施的提供，并在决定是否继续提供匹配交易设施时，公司将考虑预期（和已沟通的）股东对该设施的需求，以及公司成员登记册的组成和公司及股东的成本。</p>
<p>普通股的指示性定价以及交易历史将可在 JP Jenkins 网站上查阅，网址为 https://jpjenkins.com/。</p>
<p>咨询：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., 首席执行官</td>
<td>通过 Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, 首席财务官</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel（NOMAD 和唯一的公司经纪人）</td>
<td>电话：+44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>电话：+44 (0) 20 7933 8780 或 polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>手机：+44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
<p>关于 Polarean</p>
<p>Polarean 是一家产生收入的医学影像技术公司，通过引入 MRI 的强大和安全性，正在通过直接可视化肺功能来革新肺部医学。这个社区迫切需要现代解决方案来准确评估肺功能。该公司致力于优化肺健康，防止可避免的损失，通过揭示隐藏的疾病，解决全球超过 5 亿名患有慢性呼吸疾病患者的未满足医疗需求。Polarean 在超极化科学领域处于领先地位，成功开发了首个也是唯一的超极化氙气 MRI 吸入对比剂 XENOVIEW®，该产品现已获得美国 FDA 批准。Polarean 致力于研究、开发和商业化创新的影像解决方案，拥有其无创且无辐射的肺功能 MRI 平台。该综合药物 - 设备平台包括专有的氙气混合物、气体超极化系统，以及软件和配件，促进现代呼吸影像操作的全面集成。Polarean 成立于 2012 年，办公室位于北卡罗来纳州达勒姆和英国伦敦，致力于提高全球对其 XENOVIEW MRI 技术平台的认识和广泛访问。</p>
<p>有关 Polarean 的最新消息和信息，请访问网站 www.polarean.com</p>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此类分析以匿名方式与他人共享，作为我们商业服务的一部分。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。END ROMQELFFELLBFBL</p>

<p>Polarean Imaging PLC 宣布其股东大会上的所有决议均已通过。该公司将于 2025 年 12 月 23 日取消其 AIM 上市，并将在 2026 年 1 月 12 日之前重新注册为私人有限公司。将提供配对交易设施，以协助股东在取消上市后交易股份。该设施将定期进行审查，并可能在短时间内撤回</p>

<p>RNS Number : 6387L Polarean Imaging PLC 15 December 2025</p>
<div class="lb-trans"><p>RNS 编号：6387L Polarean Imaging PLC2025 年 12 月 15 日</p>
</div><p>15 December 2025</p>
<div class="lb-trans"><p>2025 年 12 月 15 日</p>
</div><p>Polarean Imaging Plc</p>
<div class="lb-trans"><p>Polarean Imaging Plc</p>
</div><p>(&#34;Polarean&#34; or the &#34;Company&#34;)</p>
<div class="lb-trans"><p>（&#34;Polarean&#34;或&#34;公司&#34;）</p>
</div><p>Result of General Meeting</p>
<div class="lb-trans"><p>股东大会结果</p>
</div><p>Information on Matched Bargain Facility to assist shareholders</p>
<div class="lb-trans"><p>关于帮助股东的匹配交易设施的信息</p>
</div><p>Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that at the general meeting of the Company (&#34;General Meeting&#34;) held earlier today, all resolutions were duly passed on a poll.</p>
<div class="lb-trans"><p>Polarean Imaging plc（AIM：POLX），一家商业阶段的医疗技术公司和功能性肺部成像的全球领导者，使用超极化氙 MRI，宣布在今天早些时候举行的公司股东大会（&#34;股东大会&#34;）上，所有决议均已通过投票通过。</p>
</div><p>Details of the poll results are set out below:</p>
<div class="lb-trans"><p>投票结果的详细信息如下：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution Number</td>
<td>Name</td>
<td>Votes for</td>
<td>% of votes for</td>
<td>Votes against</td>
<td>% of votes against</td>
<td>Votes withheld*</td>
</tr>
<tr>
<td>1</td>
<td>Cancellation Resolution</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>Re-registration and adoption of new articles of association Resolution</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>决议编号</td>
<td>名称</td>
<td>支持票数</td>
<td>支持票比例</td>
<td>反对票数</td>
<td>反对票比例</td>
<td>投票弃权 *</td>
</tr>
<tr>
<td>1</td>
<td>取消决议</td>
<td>534,365,742</td>
<td>80.71%</td>
<td>127,743,445</td>
<td>19.29%</td>
<td>2,347,443</td>
</tr>
<tr>
<td>2</td>
<td>重新注册和采纳新章程决议</td>
<td>534,390,927</td>
<td>80.71%</td>
<td>127,740,655</td>
<td>19.29%</td>
<td>2,325,048</td>
</tr>
</tbody>
</table>
</div><p>*Note: A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.</p>
<div class="lb-trans"><p>* 注：根据英国法律，&#34;投票弃权&#34;不算作投票，并不计入支持或反对决议的计算中。</p>
</div><p>Valid proxy instructions were received in respect of 664,456,630 Ordinary Shares representing approximately 55.05% of the issued share capital of the Company.</p>
<div class="lb-trans"><p>有效的代理指示已收到，涉及 664,456,630 股普通股，约占公司已发行股本的 55.05%。</p>
</div><p>The total number of Ordinary Shares in issue as at 15 December 2025 is 1,207,032,781.</p>
<div class="lb-trans"><p>截至 2025 年 12 月 15 日，已发行普通股总数为 1,207,032,781 股。</p>
</div><p>The full text of the Resolutions proposed and passed at the General Meeting can be found in the circular of the Company containing, inter alia, the notice of General Meeting, which was published on 14 November 2025 (the &#34;Circular&#34;) and is available on the Company's website here. Capitalised terms used but not defined in this announcement shall have the same meaning given to such terms in the Circular.</p>
<div class="lb-trans"><p>在股东大会上提出并通过的决议的完整文本可以在公司于 2025 年 11 月 14 日发布的通函中找到，其中包括股东大会通知（&#34;通函&#34;），并可在公司网站上查阅。公告中使用但未定义的专有名词应与通函中赋予的含义相同。</p>
</div><p>AIM Cancellation</p>
<div class="lb-trans"><p>AIM 取消</p>
</div><p>Following approval by Shareholders at the General Meeting, the admission of the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the last day of dealings in Ordinary Shares on AIM is expected to be 22 December 2025.</p>
<div class="lb-trans"><p>在股东大会上获得股东批准后，普通股在 AIM 的交易将被取消。取消预计将在 2025 年 12 月 23 日上午 7:00 进行，因此，普通股在 AIM 的最后交易日预计为 2025 年 12 月 22 日。</p>
</div><p>Re-registration as a private company</p>
<div class="lb-trans"><p>重新注册为私人公司</p>
</div><p>In accordance with the passing of Resolution 2, the Company will re-register as a private limited company and adopt new articles of association, which is expected to take place by 12 January 2026.</p>
<div class="lb-trans"><p>根据决议 2 的通过，公司将重新注册为私人有限公司，并采纳新章程，预计将在 2026 年 1 月 12 日之前完成。</p>
</div><p>Matched Bargain Facility</p>
<div class="lb-trans"><p>匹配交易设施</p>
</div><p>The Company has made arrangements for the Matched Bargain Facility to assist Shareholders to trade in the Ordinary Shares from the date of Cancellation. The Matched Bargain Facility will be provided by J P Jenkins, which is an appointed representative of Prosper Capital LLP, which is authorised and regulated by the UK Financial Conduct Authority. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with J P Jenkins, through their stockbroker, of the number of Ordinary Shares that they are prepared to buy or sell and the price at which they are prepared to do so. In the event that J P Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain (trade). Upon the Cancellation becoming effective, the Matched Bargain Facility will commence, and details will be made available to Shareholders on the Company's website (www.polarean.com). It should be noted, however, that there is no guarantee as to the liquidity such a facility would afford the Ordinary Shares post Cancellation.</p>
<div class="lb-trans"><p>公司已安排匹配交易设施，以帮助股东在取消之日起交易普通股。匹配交易设施将由 J P Jenkins 提供，J P Jenkins 是 Prosper Capital LLP 的指定代表，后者已获得英国金融行为监管局的授权和监管。在匹配交易设施下，股东或希望购买或出售普通股的人可以通过其股票经纪人向 J P Jenkins 留下他们愿意购买或出售的普通股数量及其愿意的价格。如果 J P Jenkins 能够将该订单与相反的卖出或买入指令匹配，它将联系双方并进行交易。取消生效后，匹配交易设施将开始，详细信息将提供给股东，并可在公司网站（www.polarean.com）上查阅。然而，需要注意的是，无法保证该设施在取消后能为普通股提供流动性。</p>
</div><p>Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.</p>
<div class="lb-trans"><p>股东将继续能够以无证书形式（即在 CREST 中）持有其股份，并应与其现有的股票经纪人核实他们是否愿意或能够交易未上市股份。</p>
</div><p>The Matched Bargain Facility is intended to operate for a minimum of twelve months after Cancellation. The current intention is that it will continue beyond that time, but Shareholders should note it could be withdrawn at short notice and therefore inhibit Shareholders' ability to trade the Ordinary Shares. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, as well as the composition of the Company's register of members and the costs to the Company and shareholders.</p>
<div class="lb-trans"><p>匹配交易设施预计将在取消后至少运行十二个月。目前的意图是它将继续超过该时间段，但股东应注意，它可能会在短时间内撤回，从而限制股东交易普通股的能力。董事会将持续审查匹配交易设施的提供，并在决定是否继续提供匹配交易设施时，公司将考虑预期（和已沟通的）股东对该设施的需求，以及公司成员登记册的组成和公司及股东的成本。</p>
</div><p>The indicative pricing for the Ordinary Shares, as well as the transaction history, will be available on the JP Jenkins website at https://jpjenkins.com/.</p>
<div class="lb-trans"><p>普通股的指示性定价以及交易历史将可在 JP Jenkins 网站上查阅，网址为 https://jpjenkins.com/。</p>
</div><p>Enquiries:</p>
<div class="lb-trans"><p>咨询：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., Chief Executive Officer</td>
<td>Via Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, Chief Financial Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel (NOMAD and Sole Corporate Broker)</td>
<td>Tel: +44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>Tel: +44 (0) 20 7933 8780 or polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>Mob: +44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Polarean Imaging plc</td>
<td>www.polarean.com / www.polarean-ir.com</td>
</tr>
<tr>
<td>Christopher von Jako, Ph.D., 首席执行官</td>
<td>通过 Walbrook PR</td>
</tr>
<tr>
<td>Charles Osborne, 首席财务官</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Stifel（NOMAD 和唯一的公司经纪人）</td>
<td>电话：+44 (0) 20 7710 7600</td>
</tr>
<tr>
<td>Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Walbrook PR</td>
<td>电话：+44 (0) 20 7933 8780 或 polarean@walbrookpr.com</td>
</tr>
<tr>
<td>Anna Dunphy / Marcus Ulker</td>
<td>手机：+44 (0) 7876741001 / +44 (0) 7867984 082</td>
</tr>
</tbody>
</table>
</div><p>About Polarean</p>
<div class="lb-trans"><p>关于 Polarean</p>
</div><p>Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.</p>
<div class="lb-trans"><p>Polarean 是一家产生收入的医学影像技术公司，通过引入 MRI 的强大和安全性，正在通过直接可视化肺功能来革新肺部医学。这个社区迫切需要现代解决方案来准确评估肺功能。该公司致力于优化肺健康，防止可避免的损失，通过揭示隐藏的疾病，解决全球超过 5 亿名患有慢性呼吸疾病患者的未满足医疗需求。Polarean 在超极化科学领域处于领先地位，成功开发了首个也是唯一的超极化氙气 MRI 吸入对比剂 XENOVIEW®，该产品现已获得美国 FDA 批准。Polarean 致力于研究、开发和商业化创新的影像解决方案，拥有其无创且无辐射的肺功能 MRI 平台。该综合药物 - 设备平台包括专有的氙气混合物、气体超极化系统，以及软件和配件，促进现代呼吸影像操作的全面集成。Polarean 成立于 2012 年，办公室位于北卡罗来纳州达勒姆和英国伦敦，致力于提高全球对其 XENOVIEW MRI 技术平台的认识和广泛访问。</p>
</div><p>For the latest news and information about Polarean, please visit the website at www.polarean.com</p>
<div class="lb-trans"><p>有关 Polarean 的最新消息和信息，请访问网站 www.polarean.com</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ROMQELFFELLBFBL</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此类分析以匿名方式与他人共享，作为我们商业服务的一部分。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。END ROMQELFFELLBFBL</p>
</div>

REG - Polarean Imaging PLC - 股东大会结果